New MRI study to see if triple inhaler opens lungs better in COPD
NCT ID NCT07192016
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study will test a once-daily triple inhaler (Trelegy) in 60 adults with moderate-to-severe COPD who still have breathlessness or poor health despite current treatment. Researchers will use a special MRI (129-Xenon) to measure how well air moves through the lungs before and after 12 weeks of treatment. The goal is to see if the inhaler improves lung ventilation and how that relates to standard breathing tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluticasone furoate/umeclidinium/vilanterol (Trelegy) triple inhaler
What this could lead to
If successful, this study could show that a once-daily triple inhaler improves lung ventilation and quality of life in COPD patients, and help doctors better predict who will benefit most.
What could go wrong
This is a small, early-phase (phase 4) mechanistic study with only 60 participants, so results may not apply to all COPD patients. The main goal is to understand how the drug works on lung imaging, not to prove it cures or reverses the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.